Valencia-based neuro-rehabilitation SME coordinating EU research on disorders of consciousness and mixed reality stroke therapy.
IRENEA is a Spanish neuro-rehabilitation SME based in Valencia that conducts applied clinical research at the intersection of neuroscience and rehabilitation technology. Their work spans two distinct but connected areas: evidence-based clinical management of disorders of consciousness (including diagnosis, prognosis, and non-invasive brain stimulation), and technology-assisted motor rehabilitation for stroke survivors using mixed reality. In both projects they acted as coordinator, meaning they design and lead research consortia rather than contribute as a supporting partner. Their real-world output is clinical knowledge, assessment protocols, and therapeutic technology that can be transferred into hospital and rehabilitation settings.
DoCMA (2018–2023) focused specifically on transferring evidence-based skills in DoC diagnosis, prognosis, and consensus-driven care management across international clinical teams.
DoCMA included controlled trial work on non-invasive brain stimulation techniques as part of the clinical protocol developed for disorders of consciousness.
StrokeCare (2021–2024) deployed mixed reality environments for upper-limb motor recovery in stroke patients, addressing attention deficits alongside motor impairment.
StrokeCare is the first project where IRENEA applied immersive mixed reality as a therapeutic delivery platform, signalling a shift toward technology-mediated treatment.
DoCMA was funded under MSCA-RISE, a scheme designed specifically for staff exchanges and cross-border transfer of professional expertise — confirming a training and dissemination role.
In their earlier work (2018–2023), IRENEA concentrated on the most clinically complex end of neurology: patients with disorders of consciousness, where the challenge is not treatment but correct diagnosis, prognosis, and care coordination across institutions. Their second project (2021–2024) pivoted toward active rehabilitation of stroke survivors using mixed reality, shifting the focus from assessment and knowledge transfer to technology-delivered therapy and motor recovery. The through-line is neuro-rehabilitation, but the direction of travel is clear: from passive diagnostic protocols toward interactive, device-mediated rehabilitation tools.
IRENEA appears to be moving toward technology-assisted neuro-rehabilitation, making them a plausible partner for projects combining clinical neuroscience with XR, wearables, or digital therapeutics.
IRENEA has coordinated both of their H2020 projects, which is unusual for a small SME — it signals strong project management capability and the confidence of funding agencies to give them the lead role. Their consortia are lean (12 unique partners across 2 projects, averaging 6 partners per project), suggesting they prefer focused, manageable teams over broad multi-partner arrangements. For a potential partner, this means working with an organisation that takes ownership of project delivery rather than deferring to a university host.
IRENEA has built a network of 12 distinct partners across 6 countries through two projects, reflecting a deliberately international but compact consortium approach. Their geographic spread across six European and possibly non-EU countries (consistent with MSCA-RISE staff exchange requirements) suggests active cross-border clinical partnerships rather than domestic-only collaboration.
IRENEA occupies a rare niche as a private clinical research SME that both coordinates EU-funded projects and works on the hardest diagnostic and therapeutic problems in neurology — disorders of consciousness and post-stroke rehabilitation. Unlike university groups that conduct research as an academic exercise, IRENEA's SME structure implies a closer orientation toward clinical translation and eventual product or protocol commercialisation. Their dual competence in rigorous clinical methodology (DoC consensus protocols, controlled trials) and emerging rehabilitation technology (mixed reality) makes them a bridge between neuroscience research and applied health technology development.
